The Transgenic Mouse/ES Cell Shared Resource has been in existence since 1993 and has received continuous funding from the NCI since the Vanderbilt-lngram Cancer Center (VICC) was awarded its first Cancer Center Support Grant in 1995. At the time of the last competitive renewal, this shared resource received an """"""""Outstanding"""""""" rating. This resource provides gene targeting, DNA pronuclear microinjections, ES cell microinjections, assisted reproduction and both sperm and embryo cryopreservation services to members of the VICC. These services are essential for the generation, maintenance, and long-term storage of germline-altered mice. The resource continues to function in a multidisciplinary manner and has undergone several significant changes since the last competitive evaluation that have enabled it to continue to provide gene targeting and microinjection services at reasonable prices, to develop several new services, and to improve both its quality control and data management strategies. The Transgenic Mouse/ES Cell Shared Resource continues to offer services that remain in high demand and vital to the generation of new mouse models of cancer and other diseases. This will be critical as the gene-specific information from genome-wide cancer studies is translated to mouse models of human cancer. Moreover, the technology base that this resource supports is expected to be important in allowing Vanderbilt investigators to adapt to using of human pluripotent stem cells in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-18
Application #
8733546
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
18
Fiscal Year
2014
Total Cost
$164,559
Indirect Cost
$89,303
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Goff, Laura W; Azad, Nilofer S; Stein, Stacey et al. (2018) Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. Invest New Drugs :
Payton, Rebecca R; Rispoli, Louisa A; Nagle, Kimberly A et al. (2018) Mitochondrial-related consequences of heat stress exposure during bovine oocyte maturation persist in early embryo development. J Reprod Dev 64:243-251
Kovtun, Oleg; Tomlinson, Ian D; Bailey, Danielle M et al. (2018) Single Quantum Dot Tracking Illuminates Neuroscience at the Nanoscale. Chem Phys Lett 706:741-752
Schlegel, Cameron; Lapierre, Lynne A; Weis, Victoria G et al. (2018) Reversible deficits in apical transporter trafficking associated with deficiency in diacylglycerol acyltransferase. Traffic 19:879-892
Weigl, Korbinian; Thomsen, Hauke; Balavarca, Yesilda et al. (2018) Genetic Risk Score Is Associated With Prevalence of Advanced Neoplasms in a Colorectal Cancer Screening Population. Gastroenterology 155:88-98.e10
Johnson, Douglas B; Dahlman, Kimberly B (2018) Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition. Clin Cancer Res 24:6107-6109
Gilchuk, Pavlo; Kuzmina, Natalia; Ilinykh, Philipp A et al. (2018) Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity 49:363-374.e10
Hebron, Katie E; Li, Elizabeth Y; Arnold Egloff, Shanna A et al. (2018) Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis. Sci Rep 8:3208
Bangaru, Sandhya; Zhang, Heng; Gilchuk, Iuliia M et al. (2018) A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat Commun 9:2669
Means, Anna L; Freeman, Tanner J; Zhu, Jing et al. (2018) Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. Cell Mol Gastroenterol Hepatol 6:257-276

Showing the most recent 10 out of 2462 publications